Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 17, 2025, titled "Zydus Medtech and Braile Biomedica of Brazil announce global licensing pact to commercialise TAVI technology".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences, through its medtech arm Zydus Medtech, has entered a global licensing agreement with Brazil-based Braile Biomedica to commercialise TAVI (Transcatheter Aortic Valve Implantation) technology. TAVI is a minimally invasive procedure used to replace a diseased aortic valve without open-heart surgery, mainly for patients with aortic stenosis. Under the pact, Zydus Medtech will get rights to commercialise Braile's TAVI technology across global markets. The deal strengthens Zydus's presence in the high-growth structural heart disease segment and diversifies its medical device portfolio beyond its existing businesses. Braile Biomedica brings proven expertise in cardiac and vascular devices, which complements Zydus Medtech's manufacturing and distribution strengths.
This is a positive strategic move for Zydus shareholders, as it opens a new, high-value revenue stream in the global cardiac device market without significant R&D risk, since the technology is already proven. In the short term, the stock may see limited reaction since this is a licensing deal without disclosed financial terms, but long-term it supports the company's medtech growth story.